Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Neuraltus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics for neurodegenerative diseases. Founded in 2004 and based in Palo Alto, California, the company is advancing several clinical-stage programs, including NP001, an investigational therapy aimed at regulating activated macrophages linked to chronic neurological conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Neuraltus's pipeline also includes potential treatments for dyskinesias associated with Parkinson's disease and lysosomal storage disorders like Fabry's and Gaucher's diseases. Each program represents innovative, first-in-class approaches to addressing critical unmet medical needs in these areas. The company's foundational technology and intellectual property were developed by its founders, who have strong academic ties to leading institutions.
Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.
PerceptiMed, Inc. specializes in manufacturing and marketing medication-verification systems designed to minimize human errors in medication dispensing across pharmacies, long-term care facilities, and hospitals. The company's key offerings include the IdentRx, an automated device that ensures accurate verification of prescription pills, and IdentRx Remote, a software solution that facilitates remote verification of dispensed medications. Additionally, PerceptiMed provides MedPass, which aims to further reduce errors in pill administration, and ScripClip, an electronic tagging system. The company's innovative VeriFill technology enhances the precision of prescription fulfillment by delivering 100% verification of drug, dosage, and manufacturer, thereby improving safety and efficiency in medication management. Founded in 2011, PerceptiMed is headquartered in Mountain View, California, and serves clients throughout the United States.
Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.
Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.
Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.
Neuraltus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics for neurodegenerative diseases. Founded in 2004 and based in Palo Alto, California, the company is advancing several clinical-stage programs, including NP001, an investigational therapy aimed at regulating activated macrophages linked to chronic neurological conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Neuraltus's pipeline also includes potential treatments for dyskinesias associated with Parkinson's disease and lysosomal storage disorders like Fabry's and Gaucher's diseases. Each program represents innovative, first-in-class approaches to addressing critical unmet medical needs in these areas. The company's foundational technology and intellectual property were developed by its founders, who have strong academic ties to leading institutions.
Viracta Therapeutics specializes in developing innovative treatments for cancers linked to the Epstein-Barr Virus. The company is advancing its proprietary viral gene activation therapy, which aims to effectively target and address these virus-associated malignancies. In addition to its primary focus on Epstein-Barr Virus-related cancers, Viracta is also exploring opportunities to tackle other serious diseases associated with viral infections. Through its research and therapeutic advancements, the company seeks to improve outcomes for patients suffering from these challenging health conditions.
Private Equity Round in 2012
Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.
Neuraltus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics for neurodegenerative diseases. Founded in 2004 and based in Palo Alto, California, the company is advancing several clinical-stage programs, including NP001, an investigational therapy aimed at regulating activated macrophages linked to chronic neurological conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Neuraltus's pipeline also includes potential treatments for dyskinesias associated with Parkinson's disease and lysosomal storage disorders like Fabry's and Gaucher's diseases. Each program represents innovative, first-in-class approaches to addressing critical unmet medical needs in these areas. The company's foundational technology and intellectual property were developed by its founders, who have strong academic ties to leading institutions.
Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.
Inova Labs, Inc. is a medical device development and manufacturing company based in Austin, Texas, established in 2002. The company specializes in creating innovative direct patient care products, particularly focusing on respiratory support. Its flagship offerings include the LifeChoice oxygen concentrators, which are available in both stationary and portable models, designed to provide supplemental oxygen for patients with respiratory illnesses. The LifeChoice products feature a pulse mode system and cater to various oxygen flow needs. Inova Labs also provides essential accessories such as carrying cases, external batteries, and power adapters. The company's products are distributed through authorized providers, who sell them on their respective websites.
Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.
Naurex Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for depression and other central nervous system disorders. The company specializes in a new approach to modulating the N-methyl-D-aspartic acid receptor (NMDAR), resulting in the creation of a unique class of compounds called glycine-site functional partial agonists (GFPAs). These GFPAs interact with the NMDAR in a manner distinct from traditional agents, potentially offering new treatment options for patients. Naurex's drug development pipeline includes several programs, highlighted by the first-generation molecule GLYX-13 and the second-generation NRX-1050 series, along with additional compounds derived from its platform of novel NMDAR modulators. Through this research, Naurex aims to address the challenges posed by various CNS disorders.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.
Femta Pharmaceuticals is a private company categorized under Pharmaceutical preparations and located in San Diego, CA.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
Calistoga Pharmaceuticals, Inc. focuses on developing innovative oral therapeutics that target specific isoforms of the PI3 kinase pathway, which plays a crucial role in cell survival and immune responses. The company's approach aims to enhance treatment outcomes for patients suffering from cancer and inflammatory diseases while minimizing adverse effects. Its lead product, CAL-101, is an oral inhibitor selectively targeting the delta isoform of PI3K, showing promising clinical responses in patients with B-cell malignancies and undergoing various clinical trials. Beyond CAL-101, Calistoga Pharmaceuticals has a pipeline of additional selective PI3K inhibitors that are either in early preclinical stages or poised for initial clinical trials, further advancing its commitment to addressing cancer and inflammatory conditions.
Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.
Femta Pharmaceuticals is a private company categorized under Pharmaceutical preparations and located in San Diego, CA.
Transcend Medical, Inc. is an ophthalmic device company dedicated to developing medical devices for the treatment of glaucoma, a leading cause of irreversible blindness in adults. Founded in 2005 and based in Menlo Park, California, the company emerged from ForSight Labs and focuses on minimally invasive solutions to replace traditional invasive therapies. Its flagship product, the CyPass Micro-Stent, is designed to be inserted during routine cataract surgery to help reduce intraocular pressure. Transcend Medical also offers the Vold Gonio Lens for use in micro-invasive glaucoma surgery and provides clinical trial services. The CyPass Micro-Stent received CE mark approval in 2008 and has been evaluated in various clinical studies, including the COMPASS multi-center trial. The company operates as a subsidiary of Alcon Holdings, Inc.
Revascular Therapeutics
Series B in 2009
Revascular Therapeutics is a medical device company that develops solutions for the intravascular treatment of complex lesions and total occlusions. Revascular develops percutaneous medical devices to reopen occluded vessels.
ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.
Neuraltus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics for neurodegenerative diseases. Founded in 2004 and based in Palo Alto, California, the company is advancing several clinical-stage programs, including NP001, an investigational therapy aimed at regulating activated macrophages linked to chronic neurological conditions such as amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, and multiple sclerosis. Neuraltus's pipeline also includes potential treatments for dyskinesias associated with Parkinson's disease and lysosomal storage disorders like Fabry's and Gaucher's diseases. Each program represents innovative, first-in-class approaches to addressing critical unmet medical needs in these areas. The company's foundational technology and intellectual property were developed by its founders, who have strong academic ties to leading institutions.
Pathway Medical Technologies Inc. designs, develops, manufactures, and markets medical devices for the treatment of arterial and vascular diseases.
OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative therapeutics targeting the biological mechanisms underlying cancer growth, resistance, recurrence, and metastasis. The company is advancing several monoclonal antibodies, including Navicixizumab, which targets Delta-like ligand 4 and vascular endothelial growth factor, currently undergoing clinical trials for various advanced solid tumors, including metastatic colorectal cancer and platinum-resistant ovarian cancer. Another key candidate, Etigilimab, targets the immunological receptor TIGIT and is in Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed's research also includes preclinical programs focused on additional therapeutic candidates. The company has formed strategic alliances with prominent pharmaceutical firms to enhance its development efforts in creating novel small molecule therapeutics and biologics aimed at cancer treatment. Founded in 2004 and based in Redwood City, California, OncoMed operates as a subsidiary of Mereo BioPharma Group plc.
ForteBio is a life science company focused on developing analytical systems for protein quantification and the characterization of protein-protein interactions. The company offers the Octet family of instruments, which facilitate real-time analysis of biomolecular interactions using micro-volume samples. These instruments provide essential data on affinity, kinetics, and concentration for proteins, peptides, DNA, RNA, and small molecules. Key products in the Octet line include the Octet RED, which is designed for quantitation and kinetics analysis while also enhancing the range and resolution for small molecule screening, as well as the Octet Q and QK models that perform similar analytical functions. By enabling rapid, real-time results, ForteBio's systems support scientists in their research endeavors.
Proteolix is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies targeting protein degradation pathways to address cancer and autoimmune diseases. The company’s lead product is a pioneering proteasome inhibitor, designed to evaluate safety and efficacy in treating multiple myeloma and various malignancies. In addition to this lead product, Proteolix is advancing a pipeline of novel proteasome inhibitors, which includes an oral formulation and a selective immunoproteasome inhibitor. These therapies aim to provide healthcare professionals with effective treatment options for specific hematologic cancers by inhibiting the cellular proteasome.
Meritage Pharma, Inc. is a company focused on developing prescription products for gastrointestinal and atopic diseases. Founded in 2008 and based in San Diego, California, it specializes in budesonide, a glucocorticoid steroid used in treatments for conditions such as pediatric asthma, allergic rhinitis, and Crohn's disease. The company's primary product candidate is an oral budesonide suspension aimed at treating adolescents and young adults with eosinophilic esophagitis, an allergic inflammation affecting the gastrointestinal tract. Through its innovative approaches, Meritage Pharma seeks to address significant medical needs in these areas.
CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.
Pathway Medical Technologies Inc. designs, develops, manufactures, and markets medical devices for the treatment of arterial and vascular diseases.
Leptos Biomedical offers a proprietary neuromodulation therapy solution for chronic obesity. The company delivers its treatment, which involves the electrical activation of a nerve in the autonomic nervous system via a pacemaker-type device. Leptos Biomedical was founded in 2002 and is based in Fridley, Minnesota.
CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.
Evoke Pharma, Inc. is a specialty pharmaceutical company based in Solana Beach, California, focused on developing treatments for gastrointestinal disorders. Founded in 2007, the company is advancing its lead product candidate, Gimoti, an investigational metoclopramide nasal spray designed to relieve symptoms associated with acute and recurrent diabetic gastroparesis in women. Gimoti aims to offer a novel delivery method through the nasal mucosa, potentially improving the effectiveness of traditional oral therapies for patients suffering from gastrointestinal diseases. Evoke Pharma recognizes the significant unmet medical needs in this field and seeks to provide enhanced treatment options by developing improved formulations of existing drugs. The company has established strategic partnerships with various clinical and regulatory experts to support its product development efforts and plans to continue pursuing collaborations for new acquisitions and asset investments.
Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.
Pulmonx Corporation is a medical technology company focused on developing minimally invasive devices for diagnosing and treating chronic obstructive pulmonary disease (COPD), particularly severe emphysema. The company offers key products including the Zephyr Endobronchial Valve, which addresses hyperinflation in adult patients, and the Chartis Pulmonary Assessment System, a tool that evaluates collateral ventilation through flow and pressure measurements. Additionally, Pulmonx provides the StratX Lung Analysis Platform, a cloud-based service that utilizes computed tomography to analyze lung conditions, aiding in the identification of treatment targets for the Zephyr Valve. With a strong clinical foundation supported by numerous published studies, Pulmonx has received regulatory recognition, including FDA approval for its Zephyr Valve, which is now used by physicians in over 25 countries. The company aims to enhance the quality of life for emphysema patients worldwide, having facilitated the treatment of more than 19,000 patients with over 76,000 valves deployed. Founded in 1995 and headquartered in Redwood City, California, Pulmonx continues to lead in interventional procedures for COPD treatment.
Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.
Pathway Medical Technologies Inc. designs, develops, manufactures, and markets medical devices for the treatment of arterial and vascular diseases.
TetraLogic Pharmaceuticals is a privately held biopharmaceutical company focused on discovering and developing small molecule drugs aimed at treating serious diseases. The company specializes in therapies that modulate programmed cell death pathways. Its Smac Mimetics are designed to target and neutralize obstacles in the apoptosis pathway, enabling the selective destruction of cancer cells. Additionally, TetraLogic's Necrostatin drugs work by blocking key processes that lead to necrosis, promoting cell survival in various diseases and conditions where necrosis plays a significant role in the pathology. Through its innovative approach, TetraLogic aims to address critical unmet medical needs in oncology and beyond.
Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.
ProteinSimple is part of the Protein Platforms division of Bio-Techne (NASDAQ: TECH). They rethinking protein tools and helping thousands of researchers around the world resolve their protein analysis problems so they can reveal new insight into proteins and their role in disease. Their wide-ranging portfolio of tools includes everything from immunoassay systems that quantify protein expression to systems that probe the structure and purity of protein-based therapeutics.
Ovalis is a biotechnology company that develops catheter-based medical devices for the repair of cardiovascular defects.The company is based in Mountain View, California.
ForteBio is a life science company focused on developing analytical systems for protein quantification and the characterization of protein-protein interactions. The company offers the Octet family of instruments, which facilitate real-time analysis of biomolecular interactions using micro-volume samples. These instruments provide essential data on affinity, kinetics, and concentration for proteins, peptides, DNA, RNA, and small molecules. Key products in the Octet line include the Octet RED, which is designed for quantitation and kinetics analysis while also enhancing the range and resolution for small molecule screening, as well as the Octet Q and QK models that perform similar analytical functions. By enabling rapid, real-time results, ForteBio's systems support scientists in their research endeavors.
OncoMed Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the discovery and development of innovative therapeutics targeting the biological mechanisms underlying cancer growth, resistance, recurrence, and metastasis. The company is advancing several monoclonal antibodies, including Navicixizumab, which targets Delta-like ligand 4 and vascular endothelial growth factor, currently undergoing clinical trials for various advanced solid tumors, including metastatic colorectal cancer and platinum-resistant ovarian cancer. Another key candidate, Etigilimab, targets the immunological receptor TIGIT and is in Phase Ia/b clinical trials for advanced or metastatic solid tumors. OncoMed's research also includes preclinical programs focused on additional therapeutic candidates. The company has formed strategic alliances with prominent pharmaceutical firms to enhance its development efforts in creating novel small molecule therapeutics and biologics aimed at cancer treatment. Founded in 2004 and based in Redwood City, California, OncoMed operates as a subsidiary of Mereo BioPharma Group plc.
Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.
Xtent is a development stage medical device company focused on developing and commercializing their innovative customizable drug eluting stent systems for the treatment of coronary artery disease, or CAD. Their drug eluting stent systems are designed to enable physicians to customize both length and diameter of the stent at the site of the diseased section of the artery, or lesion, which we refer to as in-situ customization.
CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.
Cellective Therapeutics was founded with technology created by Dr. Tom Tedder, a recognized world leader in B-cell biology and Chairman of the Department of Immunology at Duke University. Dr. Tedder's team focused on research done in B cells, cells that form an important component of the normal immune system and are hyperactive in people with autoimmune disorders. This hyperactivity of B cells can cause tissue inflammation and organ system dysfunction. With autoimmune diseases like lupus, multiple sclerosis and rheumatoid arthritis, the body actually rejects itself, as if organs were transplanted from someone else. Cellective's research focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.
Cellective Therapeutics
Series A in 2004
Cellective Therapeutics is a biopharmaceutical company that engages in B Cell research for cancer and autoimmune diseases. Cellective focuses on monoclonal antibodies, which, with the company's technology, can be developed so specifically that they block the root causes of autoimmunity without interfering with the body's normal response to infections.
Aria Biosystems is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification or characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics and concentration. Aria utilizes proprietary bio-layer interferometry (BLI) that enables self-calibration and measurement of molecular interactions using simple-to-use and inexpensive instrumentation. The entire analysis can be completed within minutes and does not require labeling of either probe or target. Aria's analytical capabilities provide greater value in applications where existing methods such as HPLC, ELISA and surface plasmon resonance (SPR) have limitations in throughput, performance and cost.
Bayhill Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapeutics for autoimmune diseases. The company uses its therapeutic BHT-DNA platform to develop a pipeline of treatment candidates for autoimmune diseases. Its products in clinical pipeline include BHT-3021, which is in Phase I/II clinical trial for reducing or eliminating the immune system’s attack on the pancreas; BHT-3009, which completed its Phase II trial for the treatment of multiple sclerosis; and BHT-3034, which is in preclinical studies for the treatment of myasthenia gravis. The company was formerly known as Tolerion, Inc. and changed its name to Bayhill Therapeutics, Inc. in November 2002. Bayhill Therapeutics, Inc. was founded in 2000 and is headquartered in Palo Alto, California.
CardioMind, Inc. Inc manufactures therapeutic devices for cardiovascular diseases. The company also offers stent delivery systems, which are designed for use in lesion applications, as well as for the treatment of coronary and peripheral artery diseases. In addition, it provides invasive endovascular medical devices for treating neurological and cardiovascular diseases. The company was founded in 2003 and is based in Sunnyvale, California.